Posts

J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout

on

Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti

on

Kelonia Therapeutics delivers impressive in vivo CAR-T update

on

Create Medicines raises $122M to advance in vivo CAR-T programs

on

Kyverna Therapeutics Advances Toward First CAR-T Approval in Autoimmune Diseases with Strong SPS Trial Data

on

Evolving Lymphoma Market Sidelines Two J&J CAR-T Programmes

on

Novartis CEO on Continued Evaluation of In Vivo CAR-T Therapies Without Current Deals

on

Eli Lilly Acquires Kelonia Therapeutics for Up to $7 Billion to Bolster In Vivo CAR-T Pipeline

on

Allogene's Off-the-Shelf CAR-T Cema-Cel Shows Early Promise in Erasing Lingering Lymphoma Cells

on

AstraZeneca's In Vivo CAR-T ESO-T01 Shows Promise in Multiple Myeloma with Remissions but One Death in China Trial

on

AstraZeneca Announces Cell Therapy Manufacturing Hub and R&D Center in Shanghai

on

Gilead Sciences Acquires Arcellx in $7.8 Billion Deal to Control CAR-T Cell Therapy

on

Eli Lilly Acquires Orna Therapeutics for Up to $2.4 Billion to Advance In Vivo CAR-T Therapies

on

Biopharma Bites: uniQure Pauses AMT-191 Dosing, GSK's Nucala Gets EU Nod, Gilead CAR-T Label Update

on

AstraZeneca Acquires Complete Global Rights to AbelZeta's C-CAR031 CAR-T Therapy for Up to $630 Million

on

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting Durable Complete Response and 66.7% ORR in Advanced GC/GEJ

on

Kyverna to seek FDA engagement after positive autoimmune CAR-T data in stiff person syndrome

on

FDA Signals Higher Efficacy Bar for New CAR‑T Cancer Therapies

on

AstraZeneca’s dual-targeting CAR-T AZD0120 shows similar response rates in Western and Chinese patients

on

Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships

on